International journal of clinical oncology

01 17 October 2026

DOI 10.1007/s10147-026-03197-7

A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients

Open DOI

Yu Sunakawa, Hiroyuki Arai, Yohei Kubota et al.

Background: Long waiting times on chemotherapy days increase patient burden. Pre-visit blood sampling may streamline workflows; however, its real-world impact remains unclear. Methods: This prospective study collected data on waiting tim...

Read abstract

02 16 October 2026

DOI 10.1007/s10147-026-03216-7

Comment on: second recurrence after R0 resection of recurrent colorectal cancer: patterns and implications for surveillance

Open DOI

Min Zou, Zijie Yang, Feng Gao et al.

03 14 October 2026

DOI 10.1007/s10147-026-03199-5

Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study

Open DOI

Shinichi Makita, Hideki Goto, Koji Izutsu et al.

Background: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T-cell therapy, showed high response rates and favorable safety in patients with relapsed/refractory (R/R) FL in the international, pivotal, phase...

Read abstract

04 13 October 2026

DOI 10.1007/s10147-026-03217-6

Association between fat-free mass index and severe locomotive syndrome in patients with cancer: sex-specific cutoff values

Open DOI

Ryoga Kashima, Ryo Yoshikawa, Wataru Saho et al.

Background: Locomotive syndrome (LS) is a clinical condition used to describe reduced mobility caused by musculoskeletal dysfunction and is highly prevalent among patients with cancer. The fat-free mass index (FFMI) is an indicator of nu...

Read abstract

05 9 October 2026

DOI 10.1007/s10147-026-03212-x

Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy

Open DOI

Ya Guo, Satoshi Saito, Kenji Makita et al.

06 8 October 2026

DOI 10.1007/s10147-026-03185-x

Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study

Open DOI

Atsuki Matsukawa, Taigo Kato, Masaharu Oki et al.

Background: The efficacy of second-line cabozantinib following first-line immune checkpoint inhibitor (ICI)-based combinations, particularly after pembrolizumab plus lenvatinib (Pem + Len), remains uncharacterized. We evaluated real-worl...

Read abstract

07 7 October 2026

DOI 10.1007/s10147-026-03207-8

Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy

Open DOI

Tomonao Taira, Mitsuhito Sasaki, Go Igarashi et al.

Background: Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study....

Read abstract

08 7 October 2026

DOI 10.1007/s10147-026-03209-6

Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan

Open DOI

Eri Habano, Yusuke Sato, Miho Ogawa et al.

Background: Genomic testing has become increasingly important in prostate cancer because BRCA1/2 and other genomic alterations can inform treatment selection and may indicate an underlying hereditary cancer syndrome. However, treatment-d...

Read abstract

09 7 October 2026

DOI 10.1007/s10147-026-03215-8

Clinical characteristics, anatomical distribution, and diagnostic patterns of simple bone cysts in Japan: an analysis of the Japanese Bone and Soft Tissue Tumor registry

Open DOI

Akihiko Takeuchi, Akira Kido, Akira Ogose et al.

10 3 October 2026

DOI 10.1007/s10147-026-03211-y

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma

Open DOI

Noriomi Matsumura